A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Clinical trial NCT05601232 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05601232
Sponsor: Stella Pharma Corporation
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Angiosarcoma

Start date: 2022-11-01
Primary completion: 2024-11-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.